11 August 2021 | News
Canadian government inks MoU to build a manufacturing facility providing access to domestically manufactured vaccines against respiratory viruses
Photo Credit: Freepik
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, on Aug 10, 2021 announced the signing of a Memorandum of Understanding (MoU) with the government of Canada to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility in Canada including access to Moderna’s mRNA development engine. The goals of this MoU are to build the foundation to support Canada with direct access to rapid pandemic response capabilities and to provide access to Moderna’s vaccines in the development of respiratory viruses.
The collaboration aims to provide Canadians with access to a domestically manufactured portfolio of mRNA vaccines against respiratory viruses, including COVID-19, seasonal influenza, respiratory syncytial virus (RSV) and potential other vaccines, pending licensure. The facility is intended to also be activated on an urgent basis to support Canada with direct access to rapid pandemic response capabilities. The Company is in discussion with other governments about potential collaborations built on a similar model.
Moderna is committed to working with governments, health care professionals and other key stakeholders to meet the challenges of the COVID-19 pandemic and future pathogens. Moderna expects to invest in a state-of-the-art manufacturing facility with the collaboration of the Canadian government.
Moderna recently announced data from the final analysis of the Phase 3 COVE study demonstrating, the efficacy of Moderna COVID-19 vaccine to be 93%, with a minimum six months durable protection after administration of the second dose